Researchers Identify Intracellular Pathway of Alfacell's OnconasePaper Published in Journal of Cell Science Shows ONCONASE Uptake in Cells Differs from other RNases
BLOOMFIELD, N.J., April 05, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation today announced that European researchers have identified the pathway that ONCONASE (ranpirnase) follows to enter cells.
Published in the Journal of Cell Science (2007; 120: 1405-1411), a paper based on studies conducted at the University of Girona in Spain and the University of Montpellier II in France shows that ONCONASE enters cells using AP-2/clathrin-mediated endocytosis, enabling its subsequent delivery to the cytosol. The published data indicate that unlike other RNases, the ONCONASE endocytosis pathway is not targeted to lysosomes.
"ONCONASE has a very specific property in that it is selectively toxic to malignant cells," said Kuslima Shogen, Alfacell's chairman and chief executive officer. "The Journal of Cell Science paper is another reflection of the strong interest that the scientific and medical communities have in understanding ONCONASE's performance. Ongoing independent research like this at leading institutions is providing us with further data that is useful in our efforts to expand the potential therapeutic opportunities for our technology platform."
ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.
About Alfacell Corporation
Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit http://www.alfacell.com .
This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Media Contact David Schull or Wendy Lau Noonan Russo 212-845-4271 Investor Contact: Andreas Marathovouniotis Noonan Russo email@example.com firstname.lastname@example.org email@example.com
CONTACT: David Schull or Wendy Lau, both of Noonan Russo, +1-212-845-4271, or ; or AndreasMarathovouniotis, of Noonan Russo, +1-212-845-4253,; all for Alfacell Corporation firstname.lastname@example.org email@example.com firstname.lastname@example.org
Web site: http://www.alfacell.com/
Ticker Symbol: (NASDAQ-NMS:ACEL)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: April 2007
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.